|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3900 EUR | -1.27% |
|
+3.31% | +30.87% |
| 07-01 | Nicox Submits NCX 470 New Drug Application In The United States | CI |
| 07-01 | Nicox files U.S. marketing approval application |  |
Company Valuation: Nicox SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 109.8 | 55.83 | 22.05 | 19.32 | 24.12 | 34.81 | - |
| Change | - | -49.18% | -60.51% | -12.36% | 24.81% | 44.35% | - |
| Enterprise Value (EV) | 89.38 | 53.61 | 31.68 | 19.32 | 24.12 | 34.81 | 34.81 |
| Change | - | -40.02% | -40.9% | -39.01% | 24.81% | 44.35% | 0% |
| P/E | -2.18x | -1.78x | -1.05x | -0.88x | -9.93x | -5.64x | 39.5x |
| PBR | 1.45x | 1.04x | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.1x | -0x | -0x |
| Capitalization / Revenue | 15.2x | 17.1x | 5.25x | 2.46x | 1.44x | 11.6x | 3.48x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 11.6x | 3.48x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -5.8x | 34.8x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -1.17 | -0.63 | -0.42 | -0.32 | -0.03 | -0.07 | 0.01 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 7.233 | 3.271 | 4.2 | 7.859 | 16.77 | 3 | 10 |
| EBITDA | -16.61 | -22.86 | -17.04 | - | - | - | - |
| EBIT 1 | -46.01 | -33.96 | -17.06 | -9.854 | 4.626 | -6 | 1 |
| Net income 1 | -43.76 | -27.76 | -20.88 | -22.39 | -2.413 | -6 | 1 |
| Net Debt | -20.46 | -2.216 | 9.636 | - | - | - | - |
| Reference price 2 | 2.5550 | 1.1200 | 0.4420 | 0.2810 | 0.2980 | 0.3950 | 0.3950 |
| Nbr of stocks (in thousands) | 42,991 | 49,845 | 49,882 | 68,764 | 80,926 | 88,131 | - |
| Announcement Date | 4/28/22 | 3/20/23 | 4/22/24 | 4/29/25 | 4/30/26 | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.64x | - | - | - | 40.09M | |
| 29.28x | 5.36x | 22.26x | 2.65% | 316B | |
| 24.88x | 3.38x | 11.92x | 1.6% | 73.28B | |
| 12.48x | 6.33x | 9.65x | - | 9.87B | |
| 15.86x | 1.99x | 6.75x | 2.85% | 8.15B | |
| 21.29x | 6.02x | 17.05x | -.--% | 4.38B | |
| 36.73x | 2.34x | 27.37x | 0.75% | 3.91B | |
| 31.1x | 5.92x | 16.92x | - | 3.62B | |
| -135.16x | - | - | -.--% | 2.51B | |
| Average | 3.42x | 4.48x | 15.99x | 1.31% | 46.88B | |
| Weighted average by Cap. | 26.88x | 4.95x | 19.80x | 2.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALCOX Stock
- Valuation Nicox SA
Select your edition
All financial news and data tailored to specific country editions
